Sotera Health price target lowered to $21 from $22 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on Sotera Health to $21 from $22 and keeps an Overweight rating on the shares. The macro environment "continues to dominate the conversation" heading into the Q1 results for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm expects results in line with the "relatively light" Q1 guides with "no risk clearings yet." It still believes in the recovery and expects some relief in Q2 for a better second half of the year setup.